Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1955 3
1956 2
1957 1
1959 5
1960 4
1961 6
1962 2
1963 4
1964 4
1965 2
1966 2
1967 4
1968 4
1969 4
1970 1
1971 1
1972 1
1975 1
1976 1
1981 1
1982 1
1984 1
1985 1
1986 2
1987 1
1989 1
1993 1
1994 2
1995 1
1996 4
1997 3
2000 1
2011 1
2013 1
2017 1
2018 2
2019 2
2020 6
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Prodrugs as drug delivery system in oncology.
Delahousse J, Skarbek C, Paci A. Delahousse J, et al. Cancer Chemother Pharmacol. 2019 Nov;84(5):937-958. doi: 10.1007/s00280-019-03906-2. Epub 2019 Aug 7. Cancer Chemother Pharmacol. 2019. PMID: 31392391 Review.
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Lécuyer D, Nardacci R, Tannous D, Gutierrez-Mateyron E, Deva Nathan A, Subra F, Di Primio C, Quaranta P, Petit V, Richetta C, Mostefa-Kara A, Del Nonno F, Falasca L, Marlin R, Maisonnasse P, Delahousse J, Pascaud J, Deprez E, Naigeon M, Chaput N, Paci A, Saada V, Ghez D, Mariette X, Costa M, Pistello M, Allouch A, Delelis O, Piacentini M, Le Grand R, Perfettini JL. Lécuyer D, et al. Among authors: delahousse j. Front Immunol. 2023 Oct 18;14:1270081. doi: 10.3389/fimmu.2023.1270081. eCollection 2023. Front Immunol. 2023. PMID: 37920468 Free PMC article.
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.
Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, De Botton S. Willekens C, et al. Among authors: delahousse j. Leukemia. 2018 Sep;32(9):2008-2081. doi: 10.1038/s41375-018-0056-6. Epub 2018 Feb 26. Leukemia. 2018. PMID: 29479068 No abstract available.
Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
Willekens C, Rahme R, Duchmann M, Vidal V, Saada V, Broutin S, Delahousse J, Renneville A, Marceau A, Clappier E, Uzunov M, Rossignol J, Pascal L, Simon L, Micol JB, Pasquier F, Raffoux E, Preudhomme C, Quivoron C, Itzykson R, Penard-Lacronique V, Paci A, Fenaux P, Attar EC, Frattini M, Braun T, Ades L, De Botton S. Willekens C, et al. Among authors: delahousse j. Leuk Lymphoma. 2021 Feb;62(2):438-445. doi: 10.1080/10428194.2020.1832661. Epub 2020 Oct 12. Leuk Lymphoma. 2021. PMID: 33043739
89 results